Author/Creator: Scheiflinger, F. - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Scheiflinger, F.

1. Comparative analysis of marketed factor VIII products: recombinant products are not alike vis‐a‐vis soluble protein aggregates and subvisible particles. (11th May 2018)

Authors:: Anzengruber, J.; Lubich, C.; Prenninger, T.; Gringeri, A.; Scheiflinger, F.; Reipert, B. M.; Malisauskas, M.
Journal:: Journal of thrombosis and haemostasis
Issue:: Volume 16:Number 6(2018)
Page Start:: 1176
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS‐13 activity levels in inhibitor‐treated rats by the use of defined doses of recombinant ADAMTS‐13. (12th October 2015)

Authors:: Plaimauer, B.; Schiviz, A.; Kaufmann, S.; Höllriegl, W.; Rottensteiner, H.; Scheiflinger, F.
Journal:: Journal of thrombosis and haemostasis
Issue:: Volume 13:Number 11(2015:Nov.)
Page Start:: 2053
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. Comparative analysis of marketed factor VIII products: reply. (24th December 2018)

Authors:: Reipert, B. M.; Anzengruber, J.; Scheiflinger, F.
Journal:: Journal of thrombosis and haemostasis
Issue:: Volume 17:Number 1(2019)
Page Start:: 233
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Preclinical assessment of a new recombinant ADAMTS‐13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura. (2nd July 2016)

Authors:: Kopić, A.; Benamara, K.; Piskernik, C.; Plaimauer, B.; Horling, F.; Höbarth, G.; Ruthsatz, T.; Dietrich, B.; Muchitsch, E.‐M.; Scheiflinger, F.; Turecek, M.; Höllriegl, W.
Journal:: Journal of thrombosis and haemostasis
Issue:: Volume 14:Number 7(2016:Jul.)
Page Start:: 1410
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. In‐depth comparison of N‐glycosylation of human plasma‐derived factor VIII and different recombinant products: from structure to clinical implications. (27th July 2018)

Authors:: Canis, K.; Anzengruber, J.; Garenaux, E.; Feichtinger, M.; Benamara, K.; Scheiflinger, F.; Savoy, L.‐A.; Reipert, B. M.; Malisauskas, M.
Journal:: Journal of thrombosis and haemostasis
Issue:: Volume 16:Number 8(2018)
Page Start:: 1592
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. (15th July 2018)

Authors:: Hartmann, R.; Feenstra, T.; Valentino, L.; Dockal, M.; Scheiflinger, F.
Journal:: Journal of thrombosis and haemostasis
Issue:: Volume 16:Number 8(2018)
Page Start:: 1580
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

7. A novel flow‐based assay reveals discrepancies in ADAMTS‐13 inhibitor assessment as compared with a conventional clinical static assay. (29th July 2014)

Authors:: Grillberger, R.; Gruber, B.; Skalicky, S.; Schrenk, G.; Knöbl, P.; Plaimauer, B.; Turecek, P. L.; Scheiflinger, F.; Rottensteiner, H.
Journal:: Journal of thrombosis and haemostasis
Issue:: Volume 12:Number 9(2014:Sep.)
Page Start:: 1523
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

8. The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule. (2nd December 2014)

Authors:: Valentino, L. A.; Cong, L.; Enockson, C.; Song, X.; Scheiflinger, F.; Muchitsch, E. M.; Turecek, P. L.; Hakobyan, N.
Journal:: Haemophilia
Issue:: Volume 21:Number 1(2015:Jan.)
Page Start:: 58
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

9. Tissue factor‐independent inhibition of thrombin generation by tissue factor pathway inhibitor‐α. (29th November 2014)

Authors:: Thomassen, M. C. L. G. D.; Heinzmann, A. C. A.; Herfs, L.; Hartmann, R.; Dockal, M.; Scheiflinger, F.; Hackeng, T. M.; Rosing, J.
Journal:: Journal of thrombosis and haemostasis
Issue:: Volume 13:Number 1(2015:Jan.)
Page Start:: 92
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

10. Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. Issue 6 (3rd July 2013)

Authors:: Waters, E. K.; Genga, R. M.; Thomson, H. A.; Kurz, J. C.; Schaub, R. G.; Scheiflinger, F.; McGinness, K. E.
Journal:: Journal of thrombosis and haemostasis
Issue:: Volume 11:Issue 6(2013)
Page Start:: 1137
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗